Common variant of farnesoid-x-receptor gene enhances the response to lipid-lowering therapy

被引：0
|
作者：
Nohara, A.
Tada, H.
Katsuda, S.
Kawashiri, M.
Inazu, A.
Kobayashi, J.
Yamagishi, M.
Mabuchi, M.
机构：
[1] Kanazawa Univ, Grad Sch Med Sci, Dept Lipidol, Kanazawa, Ishikawa 920, Japan
[2] Kanazawa Univ, Grad Sch Med Sci, Div Cardiovasc Med, Kanazawa, Ishikawa 920, Japan
[3] Kanazawa Univ, Sch Hlth Sci, Kanazawa, Ishikawa 920, Japan
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2007年 / 8卷 / 01期
关键词：
D O I：
10.1016/S1567-5688(07)70966-2
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：6 / 6
页数：1
相关论文
共 50 条
  • [1] Impact of common variant of farnesoid-X-receptor gene on cardiovascular risk factors
    Nohara, Atsushi
    Tada, Hayato
    Katsuda, Shoji
    Kawashiri, Masa-aki
    Inazu, Akihiro
    Kobayashi, Junji
    Yamagishi, Masakazu
    Mabuchi, Hiroshi
    CIRCULATION, 2006, 114 (18) : 41 - 41
  • [2] Nuclear bile acid receptor gene variant improves efficacy of lipid-lowering therapy
    Nohara, Atsushi
    Tada, Hayato
    Katsuda, Shoji
    Kawashiri, Masa-Aki
    Inazu, Alkilhim
    Kobayashi, Junji
    Yamagishi, Masalkazu
    Malbuchi, Hiroshi
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (06) : E61 - E61
  • [3] Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment
    Zambon, A
    Deeb, SS
    Brown, BG
    Hokanson, JE
    Brunzell, JD
    CIRCULATION, 2001, 103 (06) : 792 - 798
  • [4] Heterogeneity of response to lipid-lowering therapy
    Bach, RG
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (07) : 2136 - 2137
  • [5] Heterogeneity of response to lipid-lowering therapy - Reply
    Penny, WF
    Peterson, KL
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (07) : 2137 - 2137
  • [6] How common is rhabdomyolysis in patients receiving lipid-lowering therapy?
    Paul S Phillips
    Nature Clinical Practice Cardiovascular Medicine, 2005, 2 : 130 - 131
  • [7] Flow common is rhabdomyolysis in patients receiving lipid-lowering therapy?
    Phillips, PS
    NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2005, 2 (03): : 130 - 131
  • [8] Primary prevention lipid-lowering drug therapy - Response
    Gotto, AM
    Kuller, LH
    CIRCULATION, 2002, 106 (07) : E35 - E36
  • [9] Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy
    Hiroshi Takane
    Masanori Miyata
    Naoto Burioka
    Chiaki Shigemasa
    Eiji Shimizu
    Kenji Otsubo
    Ichiro Ieiri
    Journal of Human Genetics, 2006, 51 : 822 - 826
  • [10] Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy
    Takane, Hiroshi
    Miyata, Masanori
    Burioka, Naoto
    Shigemasa, Chiaki
    Shimizu, Eiji
    Otsubo, Kenji
    Ieiri, Ichiro
    JOURNAL OF HUMAN GENETICS, 2006, 51 (09) : 822 - 826
12345